Mirum Pharmaceuticals Inc... (MIRM)
NASDAQ: MIRM
· Real-Time Price · USD
72.95
1.20 (1.67%)
At close: Oct 03, 2025, 3:59 PM
74.40
1.99%
After-hours: Oct 03, 2025, 07:53 PM EDT
1.67% (1D)
| Bid | 52.26 |
| Market Cap | 3.66B |
| Revenue (ttm) | 429.16M |
| Net Income (ttm) | -58.56M |
| EPS (ttm) | -1.19 |
| PE Ratio (ttm) | -61.3 |
| Forward PE | 512.5 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 91.8 |
| Volume | 261,990 |
| Avg. Volume (20D) | 690,306 |
| Open | 71.78 |
| Previous Close | 71.75 |
| Day's Range | 71.67 - 73.26 |
| 52-Week Range | 36.88 - 78.09 |
| Beta | 0.81 |
| Ex-Dividend Date | n/a |
About MIRM
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol MIRM
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for MIRM stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsMirum Pharmaceuticals Inc. is scheduled to release its earnings on
Nov 11, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+12.04%
Mirium Pharmaceuticals shares are trading higher a...
Unlock content with
Pro Subscription
1 month ago
+2.99%
Mirium Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY25 sales guidance above estimates.
1 month ago · seekingalpha.com
Mirum Pharmaceuticals: Q2 Results Continue To Show Positive MomentumMirum Pharmaceuticals continues to outperform, beating revenue and earnings expectations for two consecutive quarters and raising guidance. Livmarli, Mirum's flagship drug, is driving strong revenue g...
1 month ago · seekingalpha.com
Mirum Pharmaceuticals, Inc. (MIRM) Q2 2025 Earnings Call TranscriptMirum Pharmaceuticals, Inc. (NASDAQ:MIRM ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Andrew McKibben - Senior Vice President, Strategic Finance & Investor Relatio...
